

412251-2025 - Frivillig förhandsinsyn

Sverige – Masspektrometer – timsTOF Pro2 mass spectrometer

OJ S 120/2025 26/06/2025

Meddelande om frivillig förhandsinsyn

Varor

1. Upphandlare

1.1. Upphandlare

Officiellt namn: Karolinska Institutet

E-postadress: amanda.larsen@ki.se

2. Förfarande

2.1. Förfarande

Titel: timsTOF Pro2 mass spectrometer

Beskrivning: Karolinska Institute (KI) department Microbiology, Tumor and Cell Biology is focused on high-throughput interaction proteomics using co-fractionation mass spectrometry approaches coupled to short-gradient data-independent acquisition (DIA) for protein-interaction profiling across various biological matrixes including bacteria, phages, viruses, human cells, clinical isolates, and tissue biopsies. The nature of our research requires the ability to perform fast, high-sensitivity LC-MS/MS measurements using gradients shorter than 10 minutes, while maintaining deep proteome coverage, low limits of detection, and sub-one-second cycle times. These analytical requirements are essential to support our ongoing large-scale studies and the rapid processing of complex sample sets. The departments workflow imposes several technical constraints that few instruments can satisfy. We require the ability to perform deep proteome profiling using sub-10-minute gradients while retaining high quantitative accuracy and sensitivity. The mass spectrometer must also support CCS-aware analysis, ensure compatibility with existing and planned nano-LC chromatography systems, and deliver consistent performance across large sample batches. Acquisition software must support real-time processing, database searching, and integration with automation tools for quality control and high-throughput sample management. Moreover, the system must be able to run DIA strategies that leverage ion mobility separation to enhance specificity and identification confidence. These preconditions are driven by our need to handle growing sample numbers with fast acquisition time, without compromising analytical quality or reproducibility. The Bruker timsTOF Pro2 is the only instrument currently available that fulfills all technical and scientific requirements for our proteomics workflow. Its proprietary dual TIMS design allows simultaneous accumulation and mobility separation of ions, enabling the high-speed PASEF method, which dramatically improves sequencing speed and sensitivity. No other system supports this acquisition strategy or integrates ion mobility and mass spectrometry with such a high duty cycle. The system also supports CCS-calibrated DIA (dia-PASEF) and targeted quantitation (prm-PASEF), making it uniquely capable of handling both discovery and targeted proteomics applications in a high-throughput setting. These features are essential for our work with large sample cohorts analyzed under short LC gradients. Other vendors do not offer equivalent technologies or acquisition modes. In light of these technical constraints, and the lack of suitable alternatives despite thorough market research, the

conditions for awarding the contract through a negotiated procedure without prior publication are met. KI will sign a contract with Bruker after a standstill period of 10 days after publishing this Voluntary ex ante transparency notice.

Förfarandets identifierare: 9ea865e2-7b76-45d9-8792-a4d8ca361430

Intern identifierare: 2-2671/2025

Typ av förfarande: Förhandlat förfarande utan föregående meddelande om upphandling

2.1.1. Föremålet för upphandlingen

Kontraktets art: Varor

Huvudklassificering (cpv): 38433100 Masspektrometer

2.1.2. Leveransplats

Land: Sverige

Var som helst i det aktuella landet

2.1.4. Allmänna upplysningar

Rättslig grund:

Direktiv 2014/24/EU

5. Del (anbudsområde)

5.1. Del (anbudsområde): LOT-0000

Titel: timsTOF Pro2 mass spectrometer

Beskrivning: Karolinska Institute (KI) department Microbiology, Tumor and Cell Biology is focused on high-throughput interaction proteomics using co-fractionation mass spectrometry approaches coupled to short-gradient data-independent acquisition (DIA) for protein-interaction profiling across various biological matrixes including bacteria, phages, viruses, human cells, clinical isolates, and tissue biopsies. The nature of our research requires the ability to perform fast, high-sensitivity LC-MS/MS measurements using gradients shorter than 10 minutes, while maintaining deep proteome coverage, low limits of detection, and sub-one-second cycle times. These analytical requirements are essential to support our ongoing large-scale studies and the rapid processing of complex sample sets. The departments workflow imposes several technical constraints that few instruments can satisfy. We require the ability to perform deep proteome profiling using sub-10-minute gradients while retaining high quantitative accuracy and sensitivity. The mass spectrometer must also support CCS-aware analysis, ensure compatibility with existing and planned nano-LC chromatography systems, and deliver consistent performance across large sample batches. Acquisition software must support real-time processing, database searching, and integration with automation tools for quality control and high-throughput sample management. Moreover, the system must be able to run DIA strategies that leverage ion mobility separation to enhance specificity and identification confidence. These preconditions are driven by our need to handle growing sample numbers with fast acquisition time, without compromising analytical quality or reproducibility. The Bruker timsTOF Pro2 is the only instrument currently available that fulfills all technical and scientific requirements for our proteomics workflow. Its proprietary dual TIMS design allows simultaneous accumulation and mobility separation of ions, enabling the high-speed PASEF method, which dramatically improves sequencing speed and sensitivity. No other system supports this acquisition strategy or integrates ion mobility and mass spectrometry with such a high duty cycle. The system also supports CCS-calibrated DIA (dia-PASEF) and targeted quantitation (prm-PASEF), making it uniquely capable of handling both discovery and targeted proteomics applications in a high-throughput setting. These features are essential for our work with large sample cohorts analyzed under short LC gradients. Other

vendors do not offer equivalent technologies or acquisition modes. In light of these technical constraints, and the lack of suitable alternatives despite thorough market research, the conditions for awarding the contract through a negotiated procedure without prior publication are met. KI will sign a contract with Bruker after a standstill period of 10 days after publishing this Voluntary ex ante transparency notice.

Intern identifierare: 2-2671/2025

5.1.1. Föremålet för upphandlingen

Kontraktets art: Varor

Huvudklassificering (cpv): 38433100 Masspektrometer

5.1.2. Leveransplats

Land: Sverige

Var som helst i det aktuella landet

5.1.6. Allmänna upplysningar

Upphandlingen omfattas av Världshandelsorganisationens avtal om offentlig upphandling, GPA : ja

5.1.16. Kompletterande information, medling och prövning

Prövningsorganisation: Förvaltningsrätten

Organisation som undertecknar kontraktet: Karolinska Institutet

6. Resultat

Värdet av alla de kontrakt som tilldelas i det här förfarandet: 3 825 750,00 SEK

Direkttilldelning:

Motivering av direkttilldelning: Kontraktet kan endast tillhandahållas av en viss leverantör på grund av bristande konkurrens av tekniska skäl

Annan motivering: The Bruker timsTOF Pro2 is the only instrument currently available that fulfills all technical and scientific requirements for our proteomics workflow. Its proprietary dual TIMS design allows simultaneous accumulation and mobility separation of ions, enabling the high-speed PASEF method, which dramatically improves sequencing speed and sensitivity. No other system supports this acquisition strategy or integrates ion mobility and mass spectrometry with such a high duty cycle. The system also supports CCS-calibrated DIA (dia-PASEF) and targeted quantitation (prm-PASEF), making it uniquely capable of handling both discovery and targeted proteomics applications in a high-throughput setting. These features are essential for our work with large sample cohorts analyzed under short LC gradients. Other vendors do not offer equivalent technologies or acquisition modes. In light of these technical constraints, and the lack of suitable alternatives despite thorough market research, the conditions for awarding the contract through a negotiated procedure without prior publication are met.

6.1. Resultat – delkontraktets id: LOT-0000

6.1.2. Information om vinnarna

Verklig ägare:

Officiellt namn: Bruker Nordic AB

Anbud:

Identifierare för anbudsgivare: 2-2671/2025

Identifierare för del eller grupp av delar: LOT-0000

Information om kontraktet:

Identifierare för kontraktet: 2-2671/2025

Datum då vinnaren utsågs: 24/06/2025

Organisation som undertecknar kontraktet: Karolinska Institutet

8. Organisationer

8.1. ORG-0001

Officiellt namn: Karolinska Institutet

Registreringsnummer: 2021002973

Avdelning: CIS

Postadress: Nobels väg 5

Ort: STOCKHOLM

Postnummer: 17177

Del av land (NUTS): Stockholms län (SE110)

Land: Sverige

Kontaktpunkt: Amanda Larsen

E-postadress: amanda.larsen@ki.se

Tfn: +46 08-52480000

Webbadress: <http://www.ki.se>

Den här organisationens roller:

Upphandlare

Organisation som undertecknar kontraktet

8.1. ORG-0002

Officiellt namn: Förvaltningsrätten

Registreringsnummer: 202100-2742

Ort: Stockholm

Postnummer: 115 76

Del av land (NUTS): Stockholms län (SE110)

Land: Sverige

E-postadress: forvaltningsrattenistockholm@dom.se

Tfn: 08-561 680 00

Webbadress: <https://www.domstol.se/forvaltningsratten-i-stockholm/>

Den här organisationens roller:

Prövningsorganisation

8.1. ORG-0003

Officiellt namn: Bruker Nordic AB

Storlek på den ekonomiska aktören: Medelstort företag

Ort: Stockholm

Postnummer: 14177

Del av land (NUTS): Stockholms län (SE110)

Land: Sverige

Den här organisationens roller:

Anbudsgivare

Vinnare av de här delkontrakten: LOT-0000

8.1. ORG-0004

Officiellt namn: Merzell Holding ASA

Registreringsnummer: 980921565

Postadress: Askekroken 11

Ort: Oslo
Postnummer: 0277
Del av land (NUTS): Oslo (NO081)
Land: Norge
Kontaktpunkt: eSender
E-postadress: publication@mercell.com
Tfn: +47 21018800
Fax: +47 21018801
Webbadress: <http://mercell.com/>
Den här organisationens roller:
TED eSender

Information om meddelandet

Identifierare/version för meddelandet: d8329bff-c864-476a-a3c6-b6809929d924 - 01
Formulärtyp: Frivillig förhandsinsyn
Meddelandetyp: Meddelande om frivillig förhandsinsyn
Meddelandets undertyp: 25
Avsändningsdatum för meddelandet: 25/06/2025 12:13:10 (UTC+00:00) Västeuropeisk tid
Datum för avsändning av meddelandet (eSender): 25/06/2025 12:13:19 (UTC+00:00)
Västeuropeisk tid
Språk som det här meddelandet finns officiellt tillgängligt på: engelska
Meddelandets publiceringsnummer: 412251-2025
EUT S-nummer: 120/2025
Publiceringsdatum: 26/06/2025